We had characterized earlier the novel tumor suppressor gene hepatocellular carcinoma suppressor 1 (HCCS1), and demonstrated that expression of exogenous HCCS1 gene in human hepatocarcinoma cells could remarkably suppress their abilities to develop tumors in nude mice and to form colonies in soft agar. In this study, we provide further experimental evidence to confirm the role of HCCS1 as a tumor suppressor gene and investigate its potential in therapeutic applications by using adenovirus vectors. We show that HCCS1 overexpression, mediated by replication-deficient adenovirus, significantly suppressed the growth of human colorectal cancer cells, as well as hepatocellular carcinoma cells in vitro and in vivo. To further improve its antitumor efficacy, we inserted the HCCS1 gene into an oncolytic adenovirus. This HCCS1-armed oncolytic adenovirus exhibited a dramatic inhibitory effect on cancer cells in vitro and in vivo, and led to a complete regression of 50% of established tumor xenografts in nude mice. Taken together, our data suggest that HCCS1 is a promising therapeutic gene for the treatment of human cancers.
Introduction
The high frequency of loss of heterozygosity on chromosome 17p has been widely reported in hepatocellular carcinomas (HCC), suggesting that a putative tumor suppressor gene(s) map to this region and the gene(s) play a pivotal role in the development or progression of HCC. 1 Hepatocellular carcinoma suppressor 1 (HCCS1) was identified in our previous study as a novel tumor suppressor gene candidate by screening the minimum region of high-frequency loss of heterozygosity on chromosome 17p13.3 and positional cloning in HCC. 2, 3 The HCCS1 gene has a high frequency of mutation in one allele and a deletion of the other allele in HCC samples, implying that genetic lesions may be present in both alleles. The expression level of HCCS1 in cancer cells is significantly lower than that in noncancerous liver cells. 2 Moreover, expression of exogenous HCCS1 gene in human hepatocarcinoma cells could remarkably suppress their abilities to develop tumors in nude mice and to form colonies in soft agar. 2 Therefore, HCCS1 may be a potential therapeutic gene for treatment of human cancers.
Adenovirus vectors are widely used in cancer gene therapy. Conventional adenovirus vectors have some disadvantages such as poor gene transfection efficiency, low antitumor gene expression and nontargeting to tumor cells. 4, 5 To overcome these disadvantages, Zhang et al. 6 constructed an armed therapeutic oncolytic adenovirus system, ZD55 gene, which can efficiently augment the cytotoxic effects induced by the inserted therapeutic gene. The ZD55 gene vector, carrying both the direct oncolytic function similar to ONYX-015 and the additional activity of the therapeutic gene, offers a promising strategy for human cancer therapy. 7 In this study, we confirmed the inhibitory effect of HCCS1 on tumor growth, and further explored the possibility of its use in a therapeutic application. The results manifest that the overexpression of HCCS1 mediated by a nonreplicating adenovirus could significantly reduce growth of human colorectal carcinoma cells, as well as human hepatocarcinoma cells, both in vitro and in vivo. Moreover, an armed therapeutic oncolytic adenovirus, ZD55-HCCS1, exhibited much higher antitumor efficacy than ONYX-015 and completely eliminated approximately half of established tumor xenografts in nude mice. Therefore, the results indicate that HCCS1 has potent activity against tumors and is a promising gene for human cancer therapy.
Materials and methods

Cell lines and culture conditions
Normal human fetal liver cell line L02, normal human lung fibroblasts cell line NHLF, human colorectal cancer cell lines SW620 (with p53 mutation) 8 and LoVo, and human hepatoma cell lines BEL7404 (with p53 mutation) 9 and HepG2 were purchased from Shanghai Cell Collection, Chinese Academy of Science (Shanghai, China). The HEK293 cell line (human embryonic kidney containing the E1A region of Ad5) was obtained from Microbix Biosystems Inc. (Toronto, ON, Canada). All cells were maintained in Dulbecco's modified Eagle's medium (Hyclone, Logan, UT) supplemented with penicillin/ streptomycin and 10% fetal bovine serum at 37 1C in 5% CO 2 .
Plasmid and virus construction
The HCCS1 cDNA was obtained as described earlier. 2 The HCCS1 gene (excised by BglII/XhoI) was cloned into pShuttle-CMV (Strategene, La Jolla, CA), which was also excised by BglII/XhoI to construct pShuttle-CMV-HCCS1. In addition, the HCCS1 gene (excised by EcoRI/ BamHI) was cloned into pCA13, which was also digested by EcoRI/BamHI to construct pCA13-HCCS1. The pZD55-HCCS1 was subsequently constructed by inserting the whole foreign gene expression cassette cut from pCA13-HCCS1 using BglII into the corresponding site of pZD55. All plasmid constructs were confirmed by restrictive endonuclease digestion, PCR and DNA sequencing.
Generation, purification and titration of adenovirus
The replication-deficient adenovirus Ad-HCCS1 was constructed according to the technical protocol of the AdEasy Vector System (Strategene, La Jolla, CA). Briefly, pShuttle-CMV-HCCS1 was linearized with Pme I and cotransferred into BJ5183 bacterial cells with pAdeasy-1 (the viral DNA plasmid) to generate the recombinant adenovirus plasmid pAdeno-HCCS1 by homologous recombination. The pAdeno-HCCS1 was linearized with PacI and transfected into the HEK293 cell line to generate the adenovirus Ad-HCCS1. Ad (the adenovirus control without inserted gene) was generated by using pShuttle-CMV instead of pShuttle-CMV-HCCS1 as described above. The HCCS1 armed oncolytic adenovirus ZD55-HCCS1 was generated by homologous recombination of pZD55-HCCS1 with adenoviral packaging vector pBHGE3 (Microbix Biosystems, Toronto, Ontario, Canada) in HEK293 cells as described earlier. 6 ONYX-015 was kept in Professor Xin Yuan Liu's lab. Appropriately identified plaques were purified by two subsequent passages through HEK293 cells. The presence of the transgene in the final isolated viral stock was confirmed by PCR. For preparation of high-titer viral stocks, the recombinant adenovirus was amplified by infecting HEK293 cells and purified by cesium chloride density gradient ultracentrifugation. The preparation of recombinant adenovirus was titrated by a plaque assay using HEK293 cells.
Semiquantitative RT-PCR analysis of HCCS1 mRNA Cells were harvested after infection with Ad-HCCS1 at a multiplicity of infection (MOI) of 10 PFU per cell for 48 h. Then, total RNA was isolated using the guanidine isothiocyanate-based TRIzol solution (Watson Biotechnologies Inc., Shanghai, China), according to the manufacturer's specifications. The RNA quality was also examined by 1% agarose gel electrophoresis. First-strand cDNAs were used as templates, which were generated from total RNAs by the ThermoScript reverse transcriptase-polymerase chain reaction (RT-PCR) System (Life Technologies Inc., Grand Island, NY) according to the manufacturer's protocol. The HCCS1 gene was amplified by PCR with primer sequences 5 0 -GCAATCTCTGGC GAACATAG-3 0 and 5 0 -GCCAGGATTTGCTGTCCT AA-3 0 , and the b-microglobulin gene was coamplified with primer sequences 5 0 -ACCCCCACTGAAAAAGAT GA-3 0 and 5 0 -ATCTTCAAACCTCCATGATG-3 0 as the internal standard. PCRs were performed using 0.1 ml of cDNA solution. PCR amplification conditions were a 94 1C denaturation step for 5 min, followed by 26-30 cycles of 94 1C/30 s, 63 1C/30 s, 72 1C/1 min. The linear amplification range for either gene was determined by amplification of serially diluted cDNAs containing the specific gene. PCR samples were electrophoresed on 2.5% agarose gels, which were stained with ethidium bromide and visualized by UV illumination.
Western blot analysis of E1A, E1B 55-kDa and HCCS1 expression Cells were infected with different adenoviruses at an MOI of 10 PFU per cell. The cells were harvested 48 h after infection and then lysed in SDS-PAGE sample buffer. Total cell lysates were boiled for 3 min before loading on SDS-PAGE and then transferred to polyvinylidene difluoride membranes (Millipore Corp., Bedford, MA). The membranes were blocked with 5% nonfat milk and then incubated with various primary antibodies. After incubation with peroxidase-conjugated secondary antibodies, enhanced chemiluminescence was performed by using the SuperSignal West Pico Trial Kit (Pierce Biotechnology Inc., Rockford, IL). The actin antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The E1A antibody was purchased from NeoMarkers (M58; Fremont, CA). The E1B 55 kDa antibody was obtained from Oncogene Science (Cambridge, MA), and the HCCS1 antibody was prepared by our lab.
Cell viability assay
Cell viability assay was performed using Cell Counting Kit-8 (Dojindo Laboratories, Tokyo, Japan) according to the manufacturer's protocol. Briefly, cells were plated on 96-well plates at a density of 1 Â 10 4 per well. When cells were grown to subconfluence, they were infected with adenoviruses at an MOI of 10 PFU per cell. Ten microliters of the Cell Counting Kit-8 solution was added into each well at different time points (24, ). After 14 days, when most of the tumor volume reached 100 mm 3 in size, mice were randomly divided into three groups (six mice per group in ZD55-HCCS1 experiments, and seven mice per group in Ad-HCCS1 animal experiments). The different adenoviruses (5 Â 10 8 per dose for ZD55-HCCS1 and ONYX-015, 1 Â 10 9 per dose for Ad-HCCS1 and Ad) or PBS were injected intratumorally once every other day for four times. After the inoculation of tumor cells, tumor size was measured by a Vernier calliper every 7 days. The tumor volume (mm 3 ) was calculated as (length Â width 2 )/2. Mice were sacrificed as soon as the tumor-induced frazzle was observed, and tumors were removed weighed.
Immunohistochemistry
Tumor tissues were fixed in 4% formaldehyde, dehydrated with gradient ethanol and embedded in paraffin. Tissue sections (5 mm) were then de-waxed and re-hydrated according to a standard protocol. The sections were washed with PBS, treated with 3% H 2 O 2 and then blocked with the blocking solution (3% BSA in PBS). This was followed by incubation with antihuman HCCS1 primary antibody (diluted 1:100 in blocking solution) overnight at 4 1C. After being washed with PBS, detection of the primary antibody was done using the ChemMate DAKO EnVision Detection kit, Peroxidase/ DAB, Rabbit/Mouse (DAKO, Glostrup, Denmark) according to the manufacturer's protocol. The sections were then counterstained with hematoxylin, dehydrated and mounted.
Statistical analysis
Data are displayed as mean ± s.d. The statistical significance of difference between various groups was analyzed by analysis of variance (ANOVA) and Student-NewmanKeuls test for multiple comparisons. The statistical analysis was performed by the SPSS v11.5 software. Differences among groups were regarded as significant if Po0.05.
Results
Increased expression of HCCS1 mediated by nonreplicating adenovirus vector
To examine the overexpression of HCCS1 mediated by Ad vector in human tumor cells, the total RNA was isolated from the cells infected with Ad-HCCS1 or Ad at an MOI of 10 for 48 h, and subjected to semiquantitative RT-PCR. As shown in Figure 1a , the cells infected with Ad-HCCS1 expressed much higher HCCS1 mRNA than those infected with Ad as control. Similar results were also obtained after western blot analysis for the protein levels of HCCS1 in various infected cells, indicating that Ad-HCCS1 infection resulted in a significant overexpression of HCCS1 (Figure 1b) .
Inhibition of proliferation of cancer cells in vitro by Ad-HCCS1
Crystal violet staining assays were first performed to evaluate the cytopathic effect of Ad-HCCS1 on human cells in vitro. A significant cytopathic effect was observed in tumor cell lines infected with Ad-HCCS1 compared with cells infected with Ad, although it was not seen in normal cell lines (data not shown). To examine the HCCS1-induced cytotoxicity quantitatively, a set of human cancer cell lines (BEL7404, HepG2, W620, LoVo) and normal cell lines (L02 and HLF) were infected with Ad-HCCS1 and Ad at an MOI of 10, and cell viability was analyzed at 48 and 72 h after infection. As shown in Figure 1c , Ad-HCCS1 infection led to a notable inhibition on proliferation of all cancer cell lines compared with Ad infection (Po0.01). Slight but not significant proliferation inhibition was also observed for normal cells infected with Ad-HCCS1 compared with that with Ad (P40.05), and the percentage of surviving normal cells were much more than that of cancer cells. These results suggest that cancer cells are more sensitive to HCCS1-induced cytotoxicity.
Suppression of growth of tumors in nude mice by Ad-HCCS1
To investigate the antitumor effect of HCCS1 in vivo, Ad-HCCS1, Ad or PBS was injected into SW620 or BEL7404 tumors (B100 mm 3 ) established in nude mice every other day for a total of four injections. The tumor growth curves were plotted to monitor the treatment efficacy. As shown in Figure 2a , Intratumoral administration of Ad-HCCS1 resulted in significant growth delay of both tumors compared with administration of Ad or PBS (Po0.01), whereas Ad-treated mice exhibited similar tumor development to PBS-treated mice (P40.05). At the end of experiments (5 weeks after tumor inoculation), all of the mice were sacrificed, and tumors were then removed and weighed. As shown in Figure 2b , the average weight of SW620 tumors or BEL7404 tumors in the Ad-HCCS1 treatment group was significantly lighter than that in the Ad group or in the PBS group (Po0.01), although there was no difference between the tumor weight in the Ad group and PBS group (P40.05). According to the data on tumor weight, the inhibition rate by Ad-HCCS1 reached 64% (SW620 tumor) and 55% (BEL7404 tumor).
To verify that the therapeutic effect was due to the HCCS1 overexpression, we performed immunohistochemical analysis on the tumors. Strong HCCS1 expression was observed in tumors cells treated with Ad-HCCS1. In contrast, tumors treated with Ad displayed less or no HCCS1 expression (Figure 2c ).
Characterization of ZD55-HCCS1
As replication-deficient adenovirus-mediated gene transfer of HCCS1 clearly led to growth suppression of tumor cells both in vitro and in vivo, we further investigated the antitumor effect of HCCS1 mediated by the tumor-targeting replicative adenovirus ZD55, which was constructed by deletion of E1B 55 kDa from Ad5 similar to ONYX-015.
6 ZD55-HCCS1 was formed by inserting the HCCS1 gene into ZD55. To characterize its function, SW620 colorectal cancer cells were infected with Ad-HCCS1, ZD55-HCCS1 and ONYX-015, and the expression of E1A, E1B 55 kDa proteins was examined. Similar to ONYX-015, ZD55-HCCS1 expressed E1A protein, but not E1B 55 kDa protein in SW620 cells (Figure 3a) . Ad-HCCS1 did not express either of them. To compare the HCCS1 expression by ZD55-HCCS1 and Ad-HCCS1, SW620 and BEL7404 cells were infected with different adenoviruses at an MOI of 10 for 48 h. The cells were then harvested and subjected to western blot assay by anti-HCCS1 antibody. As shown in Figure 3b , ZD55-HCCS1 results in a higher expression of HCCS1 than Ad-HCCS1.
Strong antitumor activity of ZD55-HCCS1 in vitro and in vivo
To evaluate the inhibition on cell growth by ZD55-HCCS1, the tumor cells (SW620 and BEL7404) and the normal cells (L02) were infected with ZD55-HCCS1 and ONYX-015, and the cell viabilities were examined at various times after infection as indicated. As shown in Figure 4 , ZD55-HCCS1 infected L02 cells only showed a significant but slight retardation of growth at 96 h postinfection compared with ONYX-015 infected cells (Po0.05). The proliferation of ONYX-015 infected tumor cells was impaired, although the inhibitory effect of ZD55-HCCS1 on the tumor cell lines was more apparent than that of ONYX-015 (Po0.01). Dramatic growth suppression was observed with less than 20% viable cells by 72 h for both tumor cells infected with ZD55-HCCS1. Similar results were obtained on other tumor cell lines and normal cell lines (data not shown); indicating that HCCS1 overexpression delivered by oncolytic adenovirus induced a potent and selective antitumor activity.
To further investigate the antitumor activity of ZD55-HCCS1 in vivo, we established a model with SW620 subcutaneous xenograft tumors in nude mice. Tumors with a volume of B100 mm 3 were treated with ZD55-HCCS1, ONYX-015 or PBS by intratumoral injection. As shown in Figure 5a , treatment with ONYX-015 or ZD55-HCCS1 showed a significant tumor-retarding effect compared with PBS-treated tumors (Po0.01). The tumor inhibition by ZD55-HCCS1 was more profound than that of ONYX-015 (Po0.05). Surprisingly, administration of ZD55-HCCS1 induced regression of all established colorectal tumor xenografts, and half of them were completely eliminated at 4 weeks after treatment. There is no significant re-growth observed in most regressed tumor xenografts during the experiment, however only one re-grew after 3 weeks when treatment stopped. All mice were sacrificed when a tumor-induced frazzle was observed in the mouse treated by PBS, and then tumors were removed and weighed. As shown in Figures 5b and c, the tumors that received injection of ZD55-HCCS1 displayed less wet tumor weight compared with ONYX-015 (Po0.05) or PBS (Po0.01). The inhibition rate of tumor growth by ZD55-HCCS1 reached 97%, which was higher than that by ONYX-015 (B72% inhibition).
Discussion
HCCS1 was identified as a novel tumor suppressor gene by analysis of the highest-frequency loss of heterozygosity region on chromosome 17p13.3 positional cloning in HCC. 2, 3 Our earlier study showed that transfection of HCCS1 cDNA into HCC cell line remarkably reduced its growth in vitro and in nude mice. 2 These findings indicated that HCCS1 may be a novel therapeutic gene for human cancers. In the present study, we explored the therapeutic application of HCCS1 by using adenovirus vectors. Overexpression of HCCS1 mediated by 
Antitumor effect of adenovirus expressing HCCS1
Y Gan et al replication deficient adenovirus remarkably reduced cancer cell growth in vitro and inhibited tumor growth in vivo. To further augment the antitumor effect of HCCS1, we employed the replication-selective adenovirus (ZD55) to transfer HCCS1 into the tumor cells. ZD55 is an E1B 55 kDa gene-deleted oncolytic adenovirus that is similar to ONYX-015, but with a cloning site to insert foreign antitumor genes. In contrast to conventional adenovirus vectors, it replicates and spreads throughout the tumor tissue, thereby delivering a high dose of therapeutic gene product efficiently and selectively to tumor cells. 7 Various antitumor genes have been inserted into ZD55 to form ZD55 gene constructs and these recombinant adenoviruses displayed higher destroying effects on cancer than ZD55, ONYX-015 or Ad gene alone. [10] [11] [12] [13] [14] [15] However, such recombinant adenoviruses could hardly eliminate the established tumors. In this study, we constructed the HCCS1 armed oncolytic adenovirus, ZD55-HCCS1 and achieved a strong antitumor efficacy on xenograft tumors. The established tumors were eradicated completely in three of six mice treated with ZD55-HCCS1, and significantly regressed in the other mice. To our knowledge, this is the best result obtained from using a single recombinant adenovirus in tumor gene-virotherapy. Our results suggest that HCCS1 is an excellent candidate gene for human cancer gene therapy.
In vitro studies showed that HCCS1 overexpression leads to a significant tumor-sensitive growth-retarding effect. However, the mechanism of this effect is not clear. Recently, we demonstrated that HCCS1 overexpression can induce lysosomal efflux of aspartate protease cathepsin D, which subsequently results in activation of the mitochondria-mediated apoptotic pathway. 16 Data from that study suggest that lysosomeassociated cell death plays an important role in HCCS1-induced antitumor efficacy. Lysosomal proteases of the cathepsin family have been implicated as mediators of the lysosomal cell death triggered by various death stimuli such as death receptor activation, growth factor deprivation, microtubule-stabilizing agents, oxidative stress and staurosporine. 17, 18 In cancer cells, there are altered lysosomal trafficking and increased expression of cathepsins. 19, 20 Emerging experimental evidence suggests that such alterations may render cancer cells more sensitive to the lysosomal death pathway. 21 This may explain why the inhibitory effect on cell growth induced by HCCS1 overexpression was more powerful on cancer cells than on normal cells in our study. Notably, HCCS1 is demonstrated to be the homolog of yeast Vps53 by cDNA sequence alignment. In yeast, Vps53 is a subunit of the Golgi-associated retrograde protein complex involved in endosomal/lysosomal trafficking and the correct subcellular distribution of lysosomal hydrolases.
22 hVps53 (Human Vps53) or HCCS1 was demonstrated to have analogous characteristics to the yeast homologs, 23 and is expressed at a relatively low level in normal cells. Figure 1b indicated that although some cancer cells express deficient or significantly lower levels of HCCS1 due to its mutation and deletion on chromosome, other cancer cells can also express normal levels of HCCS1. The normal level of HCCS1 executes a relative normal transport function in endosomal/lysosomal system even in cancer cells. However, altered expression of HCCS1 or other protein that is involved in lysosomal trafficking can induce the misdistribution of lysosomal hydrolase such as cathepsin D (Press B et al. 24 and our data not shown). Although the relationship between the roles of HCCS1 as a tumor suppressor and as a trafficking protein requires further investigation, one may conceive that overexpressed HCCS1 would lead to significant inhibitory effects on cancer cell growth by executing an abnormal transport function of lysosomal proteases, which then trigger lysosomal cell death pathways. With this perspective, proteins involved in lysosomal trafficking will be novel targets for lysosome-targeted cancer therapy. 21 In conclusion, we provide experimental evidence to confirm HCCS1 as a tumor suppressor gene. The overexpression of HCCS1 mediated by replication deficient adenovirus significantly and selectively inhibits the growth of human cancer cells both in vitro and in vivo. Furthermore, the HCCS1 armed oncolytic adenovirus displays a dramatically strong antitumor efficacy. These findings provide important insights into the potential role of HCCS1 in gene-virotherapy of cancer. 
